Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy.
Wang D, Saga Y, Mizukami H, Sato N, Nonaka H, Fujiwara H, Takei Y, Machida S, Takikawa O, Ozawa K, Suzuki M.
Int J Oncol. 2012 Apr;40(4):929-34. doi: 10.3892/ijo.2011.1295. Epub 2011 Dec 13.
Related citations
The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancer.
Gao J, Yang X, Yin P, Hu W, Liao H, Miao Z, Pan C, Li N.
Int J Oncol. 2012 Apr;40(4):1203-9. doi: 10.3892/ijo.2011.1293. Epub 2011 Dec 12.
A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation.
Sorbe B, Graflund M, Nygren L, Horvath G, Swahn M, Boman K, Bangshöj R, Lood M, Malmström H.
Int J Oncol. 2012 Mar;40(3):773-81. doi: 10.3892/ijo.2011.1286. Epub 2011 Dec 7.
The potent peptide antagonist to angiogenesis, C16Y, and cisplatin act synergistically in the down-regulation of the Bcl-2/Bax ratio and the induction of apoptosis in human ovarian cancer cells.
Shinagawa A, Yoshida Y, Kurokawa T, Horiuchi Y, Tsuyoshi H, Orisaka M, Sawamura Y, Kleinman HK, Kotsuji F.
Int J Oncol. 2011 Dec;39(6):1359-64. doi: 10.3892/ijo.2011.1134. Epub 2011 Jul 20.
Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and β1 integrin.
Wagner BJ, Löb S, Lindau D, Hörzer H, Gückel B, Klein G, Glatzle J, Rammensee HG, Brücher BL, Königsrainer A.
Int J Oncol. 2011 Dec;39(6):1593-600. doi: 10.3892/ijo.2011.1167. Epub 2011 Aug 18.
Anti-angiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells.
Kim KK, Singh AP, Singh RK, Demartino A, Brard L, Vorsa N, Lange TS, Moore RG.
Int J Oncol. 2012 Jan;40(1):227-35. doi: 10.3892/ijo.2011.1198. Epub 2011 Sep 12.
Risk factors for epithelial ovarian cancer in Japan - results from the Japan Public Health Center-based Prospective Study cohort.
Weiderpass E, Sandin S, Inoue M, Shimazu T, Iwasaki M, Sasazuki S, Sawada N, Yamaji T, Tsugane S.
Int J Oncol. 2012 Jan;40(1):21-30. doi: 10.3892/ijo.2011.1194. Epub 2011 Sep 8.
Epiregulin as a marker for the initial steps of ovarian cancer development.
Amsterdam A, Shezen E, Raanan C, Slilat Y, Ben-Arie A, Prus D, Schreiber L.
Int J Oncol. 2011 Nov;39(5):1165-72. doi: 10.3892/ijo.2011.1123. Epub 2011 Jul 14.
Hedgehog signaling pathway regulates the growth of ovarian cancer spheroid forming cells.
Ray A, Meng E, Reed E, Shevde LA, Rocconi RP.
Int J Oncol. 2011 Oct;39(4):797-804. doi: 10.3892/ijo.2011.1093. Epub 2011 Jun 22.
Nuclear localization of phosphorylated ERK1 and ERK2 as markers for the progression of ovarian cancer.
Amsterdam A, Shezen E, Raanan C, Schreiber L, Prus D, Slilat Y, Ben-Arie A, Seger R.
Int J Oncol. 2011 Sep;39(3):649-56. doi: 10.3892/ijo.2011.1090. Epub 2011 Jun 17.
Non-invasive monitoring of hypoxia-inducible factor activation by optical imaging during antiangiogenic treatment in a xenograft model of ovarian carcinoma.
Martinez-Poveda B, Gomez V, Alcaide-German M, Perruca S, Vazquez S, Alba LE, Casanovas O, Garcia-Bermejo ML, Peso L, Jimenez B.
Int J Oncol. 2011 Sep;39(3):543-52. doi: 10.3892/ijo.2011.1074. Epub 2011 Jun 9.
Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer.
Singh R, Stockard CR, Grizzle WE, Lillard JW Jr, Singh S.
Int J Oncol. 2011 Aug;39(2):373-81. doi: 10.3892/ijo.2011.1059. Epub 2011 May 31.
Differential augmentative effects of buthionine sulfoximine and ascorbic acid in As2O3-induced ovarian cancer cell death: oxidative stress-independent and -dependent cytotoxic potentiation.
Ong PS, Chan SY, Ho PC.
Int J Oncol. 2011 Jun;38(6):1731-9. doi: 10.3892/ijo.2011.986. Epub 2011 Mar 23.
Ganoderma lucidum exerts anti-tumor effects on ovarian cancer cells and enhances their sensitivity to cisplatin.
Zhao S, Ye G, Fu G, Cheng JX, Yang BB, Peng C.
Int J Oncol. 2011 May;38(5):1319-27. doi: 10.3892/ijo.2011.965. Epub 2011 Mar 8.
Flexible hysteroscopy with narrow band imaging (NBI) for endoscopic diagnosis of malignant endometrial lesions.
Kisu I, Banno K, Kobayashi Y, Ono A, Masuda K, Ueki A, Nomura H, Hirasawa A, Abe T, Kouyama K, Susumu N, Aoki D.
Int J Oncol. 2011 Mar;38(3):613-8. doi: 10.3892/ijo.2011.903. Epub 2011 Jan 14.
Promoter methylation in the PTCH gene in cervical epithelial cancer and ovarian cancer tissue as studied by eight novel Pyrosequencing® assays.
Löf-Öhlin ZM, Levanat S, Sabol M, Sorbe B, Nilsson TK.
Int J Oncol. 2011 Mar;38(3):685-92. doi: 10.3892/ijo.2011.895. Epub 2011 Jan 3.
Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killercell function and angiogenesis promotion.
Nonaka H, Saga Y, Fujiwara H, Akimoto H, Yamada A, Kagawa S, Takei Y, Machida S, Takikawa O, Suzuki M.
Int J Oncol. 2011 Jan;38(1):113-20.
Oncologic trogocytosis with Hospicells induces the expression of N-cadherin by breast cancer cells.
Lis R, Capdet J, Mirshahi P, Lacroix-Triki M, Dagonnet F, Klein C, Mirshahi M, Fournié JJ, Rafii A, Poupot M.
Int J Oncol. 2010 Dec;37(6):1453-61.
Characterisation of a multimeric protein complex associated with ERp57 within the nucleus in paclitaxel-sensitive and -resistant epithelial ovarian cancer cells: the involvement of specific conformational states of beta-actin.
Cicchillitti L, Della Corte A, Di Michele M, Donati MB, Rotilio D, Scambia G.
Int J Oncol. 2010 Aug;37(2):445-54.
Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells.
Jeon HS, Ahn MY, Park JH, Kim TH, Chun P, Kim WH, Kim J, Moon HR, Jung JH, Kim HS.
Int J Oncol. 2010 Aug;37(2):419-28.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on